Evidence mapPaperPMID 28940643Full record

ArticleJournal of clinical hypertension (Greenwich, Conn.)2017

Blood pressure response to metoprolol and chlorthalidone in European and African Americans with hypertension.

Mai Mehanna, Yan Gong, Caitrin W McDonough, Amber L Beitelshees, John G Gums, Arlene B Chapman, Gary L Schwartz, Julie A Johnson, Stephen T Turner, Rhonda M Cooper-DeHoff

Open access · bronzeAbstract readComparative Study
In one paragraph

Article in Journal of clinical hypertension (Greenwich, Conn.), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.2field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 17 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Mai MehannaDepartment of Pharmacotherapy and Translational Research and Center for Pharmacogenomics, College of Pharmacy, University of Florida, Gainesville, FL, USA.ORCID http://orcid.org/0000-0002-6895-1246
Yan GongDepartment of Pharmacotherapy and Translational Research and Center for Pharmacogenomics, College of Pharmacy, University of Florida, Gainesville, FL, USA.
Caitrin W McDonoughDepartment of Pharmacotherapy and Translational Research and Center for Pharmacogenomics, College of Pharmacy, University of Florida, Gainesville, FL, USA.
Amber L BeitelsheesDepartment of Medicine, University of Maryland, Baltimore, MD, USA.
John G GumsDepartment of Pharmacotherapy and Translational Research and Center for Pharmacogenomics, College of Pharmacy, University of Florida, Gainesville, FL, USA.
Arlene B ChapmanDepartment of Medicine, University of Chicago, Chicago, IL, USA.
Gary L SchwartzDivision of Nephrology and Hypertension, Mayo Clinic, Rochester, MN, USA.
Julie A JohnsonDepartment of Pharmacotherapy and Translational Research and Center for Pharmacogenomics, College of Pharmacy, University of Florida, Gainesville, FL, USA.
Stephen T TurnerDivision of Nephrology and Hypertension, Mayo Clinic, Rochester, MN, USA.
Rhonda M Cooper-DeHoffDepartment of Pharmacotherapy and Translational Research and Center for Pharmacogenomics, College of Pharmacy, University of Florida, Gainesville, FL, USA.
American Association of Colleges of Pharmacy · USMayo Clinic · USUniversity of Chicago · USUniversity of Maryland, Baltimore · US

Funding

Pharmacogenomic Evaluation of Antihypertensive ResponsesU01GM074492 · UNIVERSITY OF FLORIDA · 2005 to 2005
$1.6M
NCATS NIH HHS KL2 TR001429NCATS NIH HHS UL1 TR000064NCATS NIH HHS UL1 TR000135NCATS NIH HHS UL1 TR000454NCATS NIH HHS UL1 TR001427NIGMS NIH HHS U01 GM074492
6 · The paper itself

Abstract

Despite the availability of many antihypertensive drug classes, half of patients with hypertension have uncontrolled blood pressure (BP). The authors sought to assess the effect of age on BP response in European American and African American patients with hypertension. Clinic BP from the PEAR2 (Pharmacogenomics Evaluation of Antihypertensive Responses 2) study was used to estimate BP responses from baseline following sequential treatment with metoprolol 100 mg twice daily and chlorthalidone 25 mg daily for 8 to 9 weeks each, with a minimum 4-week washout between treatments. BP responses to both drugs were compared in 159 European Americans and 119 African Americans by age with adjustment for baseline BP and sex. European Americans younger than 50 years responded better to metoprolol than chlorthalidone (diastolic BP: -9.6 ± 8.0 vs -5.9 ± 6.8 mm Hg, adjusted P = .003), whereas patients 50 years and older responded better to chlorthalidone than metoprolol (systolic BP: -18.7 ± 13.8 vs -13.6 ± 14.8 mm Hg, adjusted P = .008). African Americans younger than 50 years responded similarly to both drugs, whereas those 50 years and older responded better to chlorthalidone than metoprolol (-17.0 ± 13.2/-9.6 ± 7.5 vs -7.0 ± 18.6/-6.7 ± 9.3 mm Hg, adjusted P<.0001/.008). Therefore, age should be considered when selecting antihypertensive therapy in European and African American populations with hypertension.

Indexed as

Blood PressureHypertensionAdultAgedAge FactorsAntihypertensive AgentsBlack or African AmericanChlorthalidoneEthnopharmacologyFemaleHumansMaleMedication Therapy ManagementMetoprololMiddle AgedUnited StatesAntihypertensive AgentsChlorthalidoneMetoprololblood pressure responsechlorthalidonehypertensionmetoprolol

Identifiers

PMID28940643
PMCPMC5722670
OpenAlexW2757421899

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.